The UMCG website shows YouTube videos. YouTube places cookies if you watch them. Choose ‘Rather not’ if you do not want these cookies. We also place cookies of our own. These help us improve the usability of our website.
Most of the MCB research activities focus on early drug development, based on the MCB expertise in synthetic and bioanalytical chemistry with unique pharmaceutical aspects.
In collaboration with other relevant groups, the MCB researchers aim to:
The MCB research focuses on early drug development to promote personalized medicine. To achieve this, the gap between fundamental research and clinical practice as well as industry must be bridged.
The MCB research groups have set up extensive collaborations to reach these goals. They also promote collaboration with other relevant groups at the University Medical Center Groningen (UMCG) and the Faculty of Science and Engineering (FSE), especially in the field of respiratory and cancer research, by participating in joint projects aimed at improving clinical impact and providing better and more personalized diagnosis and treatment options for patients. The activities include:
Discovering tumour and background mutation profiles for each patient can help to understand the molecular mechanisms of tumour development and to find an efficient treatment for each individual patient. Proteogenomics data integration is a bioinformatics approach aimed at assessing the effect of somatic mutations (occurring during cancer development) and germline mutations (inherited from parents) and is based on genetic or transcriptomics data about proteins. Because proteins fulfil biologically active molecular functions and serve as drug targets, proteogenomics can provide essential information about pathways and about proteins that should be targeted to achieve efficient cancer treatment.
The MCB researchers are developing and implementing proteogenomics data integration strategies in the management of various oncological diseases, such as head and neck cancer, ovarian cancer, and melanoma, as well as respiratory diseases, such as COPD.
Automation and artificial intelligence (AI) are changing the way we work. The combination of automation and miniaturization is needed for development and production processes, for speeding up prototype development and reducing time-to-market, and for staying competitive in a global world. Although the credo ‘Automation + Miniaturization = Acceleration’ has been successfully applied in many technologies and research areas, this has not yet been the case for synthetic chemistry.
The MCB researchers are currently developing a technology platform aimed at autonomously discovering and optimizing early drug candidates. They use nanoscale, automated, high-throughput synthesis methods and screening methods based on artificial intelligence. The MCB researchers collaborate with leading European synchrotron facilities to explore ligand-receptor interactions using a high-throughput mode.
University Medical Center Groningen (UMCG)
Medicinal Chemistry & Bioanalysis (MCB)
P.O. Box 196
9700 AD Groningen